Corcept Therapeutics (CORT) Finished Goods (2012 - 2026)

Corcept Therapeutics (CORT) has 15 years of Finished Goods data on file, last reported at $14.7 million in Q1 2026.

• For the quarter ending Q1 2026, Finished Goods rose 72.88% year-over-year to $14.7 million; the trailing twelve-month figure through Mar 2026 stood at $14.7 million (up 72.88% YoY), and the FY2025 full-year result was $9.4 million, up 14.7% from the prior year.
• Finished Goods climbed to $14.7 million in Q1 2026, from $9.4 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $14.7 million in Q1 2026 to a low of $5.5 million in Q1 2022.
• A 5-year average of $8.2 million and a median of $8.1 million in 2023 frame the typical range for Finished Goods.
• Across the five-year window, Finished Goods retreated 19.47% in 2025 and jumped 72.88% in 2026, its largest moves.
• Tracing CORT's Finished Goods over 5 years: stood at $9.2 million in 2022, then retreated by 15.9% to $7.7 million in 2023, then gained by 6.01% to $8.2 million in 2024, then climbed by 14.7% to $9.4 million in 2025, then jumped by 56.11% to $14.7 million in 2026.
• Business Quant data shows CORT's Finished Goods at $14.7 million in Q1 2026, $9.4 million in Q4 2025, and $8.6 million in Q3 2025.